Pharmaceuticals News & Press Release Distribution

Pharmaceuticals

APAC
Global

Hummingbird Bioscience Exercises Its Option to License the Clinical Trial Results from Cancer Research UK to Support Further Development of HMBD-001

SINGAPORE and LONDON, March 6, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, and Cancer Research Horizons, the innovation arm of Cancer Research UK (CRUK), today...

2023-03-06 21:00 1978

HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myasthenia Gravis

* The trial met its primary endpoint and key secondary endpoints, with a favorable safety profile * Batoclimab is one of the most advanced FcRn inhibitors being developed in Greater China for the treatment of myasthenia gravis SEOUL, South Korea, March 6, 2023 /PRNewswire/ -- HanAll Biopharma...

2023-03-06 20:00 1444

Results of CLDN18.2-targeting Immuno-PET Probe for Non-invasive Imaging in Gastrointestinal Tumors Published

SUZHOU, China, March 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, today announces that the study ...

2023-03-03 14:56 2557

Prenetics Announces Formation of Scientific Advisory Board to Support New Business Strategy in Precision Oncology

LONDON and HONG KONG, March 2, 2023 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE), a leader in genomic and diagnostic testing, is proud to announce the formation of a new Prenetics Scientific Advisory Board (the 'SAB') to provide strategic input based on their scientific knowledge and c...

2023-03-02 20:00 2542

Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy

SUZHOU,China, March 2, 2023 /PRNewswire/ -- Porton Advanced Solutions Ltd. (Porton Advanced) and DanausGT Biotechnology Co., Ltd. (DanausGT) announced on February 27, 2023, a strategic collaboration in gene and cell therapy pipelines to expedite the development of innovative therapeutics.

2023-03-02 20:00 1874

Porton Advanced Collaborates with DanausGT to Accelerate the Development of Gene and Cell Therapy

Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376

SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" hereafter) today announced that it has entered into an exclusive Out-License Agreement (the "Agreement" hereafter) with Shanghai Allist Pharmaceuticals Co., Ltd., ("Allist" hereafter) for the further ...

2023-03-02 19:15 2855

Sanyou Biopharmaceuticals opens Cambridge MA, US office, expanding its business outreach to a central hub of biotech network

CAMBRIDGE, Mass., March 2, 2023 /PRNewswire/ -- Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is opening a new office in Cambridge Innovation Centre, CIC, marking a new era towards the company's rising ambition on serving and collaborating with world's best biotech sta...

2023-03-02 18:00 1583

111 to Announce Fourth Quarter and Fiscal Year 2022 Unaudited Financial Results- Conference Call to Follow

SHANGHAI, March 2, 2023 /PRNewswire/ -- 111, Inc. (NASDAQ: YI) ("111" or the "Company"), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced that it will report its unaudited financial results...

2023-03-02 15:35 2339

DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY

Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor LAUSANNE, Switzerland, March 2, 2023 /PRNewswire/ -- Debiopharm ( www.debiopharm.com ), an independent Swiss-based, biopharmaceutical company ...

2023-03-02 09:00 2611

ClinChoice Acquires CROMSOURCE, Expanding its Global Presence

PHILADELPHIA, SHANGHAI and VERONA, Italy, March 2, 2023 /PRNewswire/ -- ClinChoice Medical Development is pleased to announce its acquisition of CROMSOURCE S.r.l., an ISO-certified full-service contract research organization with its corporate headquarters inVerona, Italy and its US headquarters ...

2023-03-02 04:12 2700

Cambrex Recognized with CDMO Leadership Awards for 9th Consecutive Year

EAST RUTHERFORD, N.J., March 1, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), announced today that it has been recognized with 2023 CDMO Leadership Awards in the categories of Quality, Service, Expertise, and Compatibility. Additionally...

2023-03-01 19:00 2071

GenFleet receives EMA approval for phase Ib/II study of GFH925 (KRAS G12C inhibitor) in combination with ERBITUX® (cetuximab) treating patients with advanced NSCLC in first-line setting

SHANGHAI, March 1, 2023 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, announced today that European Medicine Agency (EMA) approved the phase Ib/II study of GFH925 (KRASG12C inhibitor) in combination wit...

2023-03-01 19:00 1793

A promising picture for multi-cancer early detection in Southeast Asia - latest update from biotech firm Gene Solutions

HO CHI MINH CITY, Vietnam, March 1, 2023 /PRNewswire/ -- In January 2023, Vietnam's Medical Genetics Institute & Gene Solutions published their research paper on Cancer Investigation:Clinical validation of a ctDNA-based assay for multi-cancer detection: an interim re...

2023-03-01 09:30 2137

A promising picture for multi-cancer early detection in Southeast Asia - latest update from biotech firm Gene Solutions

First in Class, Mabwell Announces the TGA Approval of 9MW3811 for IND

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its IND application of its self-developed 9MW3811 injection for tumor and pulmonary fibrosis has been approved by the Therapeutic Goods Admi...

2023-02-28 23:00 1668

Global Cold Chain Transport Track & Trace Revenues in Pharma to Reach US$2.9 billion by 2027

For pharmaceutical companies to ensure product integrity and maintain regulatory compliance, deeper product monitoring, enhanced cold chain infrastructure, and focused automation will be critical NEW YORK, Feb. 28, 2023 /PRNewswire/ -- The global pharmaceutical (pharma) industry will surpassUS$1...

2023-02-28 21:30 1663

Oricell Closes $45M Series B1 Financing to Expand Development of Key Products

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- Oricell Therapeutics Co., Ltd ("Oricell" or "the Company"), aChina-based innovative pharmaceutical company committed to the development of tumor cellular immunotherapeutics, today announced the close of a$45M Series B1 investment round after the completion ...

2023-02-28 21:00 2317

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, announced the initiation of clinical study of JWATM214 in patients with advanced hepato...

2023-02-28 17:30 2188

Chula's AICute - An Assessment Tool for Ischemic Stroke Risk

A research team from the Faculty of Medicine and Faculty of Engineering, Chulalongkorn University has jointly developed AICute, an innovative program to assess the chance of stroke caused by heart disease (Ischemic Stroke), aimed at helping hospitals that lack cardiologists to enhance the effecti...

2023-02-28 12:24 2057

Chula's AICute - An Assessment Tool for Ischemic Stroke Risk

On Rare Disease Day 2023 RemeGen Highlights Its Social Responsibility and Rare Disease Advocacy

YANTAI, China, Feb. 28, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, continues to strengthen its social responsibility and rare disease advocacy in unison with Rare Disease Day 2023'...

2023-02-28 09:16 2479

GC Biopharma Signs Agreement with Catalyst Biosciences for the Acquisition of Rare Disease Pipeline in Hematology

* Entered into an acquisition deal of 3 programs YONGIN, South Korea, Feb. 27, 2023 /PRNewswire/ -- GC Biopharma Corp. (006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that it has signed an Asset Purchase Agreement with Catalyst Biosciences (NASDAQ : ...

2023-02-28 08:53 2010

1 ... 80 81 828384 85 86 ... 294